Nutriband Develops Innovative Abuse-Deterrent Transdermal Drug Technology
TL;DR
Nutriband (NASDAQ: NTRB) presents AVERSA(TM) technology, enhancing drug safety and accessibility, giving a competitive edge in the pharmaceutical market.
AVERSA(TM) abuse-deterrent technology by Nutriband improves drug safety and efficacy through transdermal patches, reducing clinical trial requirements for new drugs.
Nutriband's AVERSA(TM) technology aims to prevent drug abuse, ensuring patient safety and well-being, making the pharmaceutical industry safer for all.
Discover Nutriband's innovative AVERSA(TM) technology, revolutionizing transdermal drug delivery and enhancing patient care in the pharmaceutical sector.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc., a pharmaceutical development company, is advancing innovative transdermal drug technology designed to improve medication safety and reduce potential drug abuse. The company's AVERSA™ technology represents a significant breakthrough in developing abuse-deterrent pharmaceutical patches.
The technology offers a comprehensive approach to preventing drug misuse, diversion, and accidental exposure, particularly for high-risk medications like fentanyl. With patents secured in multiple countries including the United States, Europe, Japan, and China, Nutriband's solution addresses a critical challenge in pharmaceutical development.
The company's strategic business model focuses on applying its transdermal technology to existing FDA-approved drugs. By doing so, Nutriband aims to enhance medication safety, improve patient comfort, and leverage a regulatory pathway that reduces clinical trial requirements for new drug approvals.
AVERSA technology's potential impact extends beyond individual product development. It represents a potential paradigm shift in pharmaceutical safety, offering a mechanism to mitigate the risks associated with drugs susceptible to abuse while maintaining therapeutic accessibility for patients who genuinely need these medications.
Nutriband's lead product, an abuse-deterrent fentanyl patch incorporating AVERSA technology, demonstrates the practical application of this innovative approach. The technology can be integrated into various transdermal patches, presenting a versatile solution for pharmaceutical manufacturers concerned with medication safety.
Curated from InvestorBrandNetwork (IBN)
